CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Key facts
- Who runs it
- Baylor College of Medicine
- Where
- Houston, United StatesSee the 2 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- Jun 2022
- Expected to end
- Aug 2040
- Type of study
- Interventional, 2 groups
- Treatments tested
- CD19.CAR-multiVST for Group A
- CD19.CAR-multiVST for Group B
- Record updated
- 21 July 2022
- Why it stopped
- We decided to move on to another product and as a result will not be moving forward with this study.
Who can take part
- Age
- 1 year to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Diagnosis of CD19+ B-ALL or NHL undergoing related allogeneic HSCT, with no evidence of disease post-HSCT (Group A) OR minimal residual disease (MRD) at time of HSCT OR relapse post-HSCT (Group B); Morphologic relapse (for Group B) will be defined by accepted definitions in Section 5.6 of the full protocol, and measured by PCR positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood; MRD will be defined as detection in blood or marrow of any of the following (at time of transplant or on post-transplant evaluation): a) Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient's leukemia cells pre-transplant on a post-transplant evaluation b) An immune globulin rearrangement known to be a disease marker for this patient c) A leukemia specific phenotype at a level of > 0.01%95, 96 d) Mixed donor chimerism
- Age ≤ 75 years old
- Patients with life expectancy ≥ 12 weeks
- Patients with a Karnofsky/Lansky score ≥ 60
- Related Donor approved for stem cell transplant
- Patient or parent/guardian capable of providing informed consent
- Patients with bilirubin less than or equal to 2x upper limit of normal
- AST less than or equal to 3x upper limit of normal
- Creatinine ≤2x upper limit of normal for age
- Hemoglobin >7.0 (can be a transfused value)
- Pulse oximetry of >90% on room air
- Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom
- Available stem cell donor-derived CD19-CAR transduced multi-virus-specific cytotoxic T lymphocytes with 15% expression of CD19-CAR determined by flow-cytometry and <10% cytotoxicity against patient or donor-derived (or other family member-derived) PHA blasts
Who cannot take part
- Severe intercurrent infection: Patients with a concurrent bacterial infection must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic antifungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection
- Currently taking corticosteroids for therapy of GVHD at a dose of >0.5mg/kg prednisone equivalent
- Evidence of graft versus host disease >grade II
- History of hypersensitivity reactions to murine protein-containing products
- CNS abnormalities: Presence of CNS-3 disease defined as detectable cerebrospinal blast cells in a sample of CSF with ≥ 5 WBCs per mm3; History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
- Patients who have received donor lymphocyte infusion (DLI) within 28 days
- Pregnant or lactating
Where in United States
- Houston Methodist HosptialHouston, United States
- Texas Children's HospitalHouston, United States
About the trial
What the trial wants to find out
This study is for patients that are having a bone marrow or stem cell transplant for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called Non-Hodgkin's Lymphoma (NHL). Although a transplant can cure leukemia or lymphoma, some people will relapse (return of the disease). In those who relapse, current treatment cures only a very small percentage. This study is being conducted to evaluate the safety of a new type of therapy that may help to decrease the risk of relapse or treat relapse after it has occurred.
Read full original descriptionShow less
The body has different ways of fighting infection and disease. This study combines two of those ways, antibodies and T cells. Antibodies are proteins that protect the body from bacterial and other diseases. T cells are infection-fighting blood cells that can kill other cells, including tumor cells. Antibodies and T cells have been used to treat patients with cancers; they have shown promise, but have not been strong enough to cure most patients.
The antibody used in this study is called anti-CD19. This antibody is attracted to cancer cells because of a substance on the outside of these cells called CD19. For this study, the anti-CD19 antibody has been changed so that instead of floating free in the blood it is now joined to T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor (also known as a CAR T cell). Although anti-CD19 antibodies or chimeric receptors can kill cancer cells, unfortunately they sometimes do not last long enough to destroy all of the cancer cells.
These CD19 chimeric receptor multivirus specific T cells are an investigational product not approved by the Food and Drug Administration.
The purpose of this study is to find the biggest dose of chimeric T cells that is safe to administer, to determine what the side effects are, to see how long the T cells last and to evaluate whether this therapy might help prevent infections and relapse in people with CD19+ leukemia or lymphoma having a bone marrow transplant.
The 2 groups in the trial
- CD19.CAR-multiVST for Group ATreatment being tested
Group A: Patients with no evidence of disease after having a bone marrow transplant. T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10\^7cells/m2 and the highest will be 10 x10\^7cells/m2.
- CD19.CAR-multiVST for Group BTreatment being tested
Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant. Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10\^7cells/m2 and the highest will be 10 x10\^7cells/m2.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I Study of the Administration of CD19 Chimeric Antigen Receptor Multivirus-Specific Cytotoxic T Lymphocytes for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
- Record updated
- 21 July 2022